Report : Middle East and Africa Late Stage Chronic Kidney Disease Drugs Market Forecast to 2027 - COVID-19 Impact and Regional Analysis by Product Type (Calcimimetics, Vitamin D, Sterols, Potassium Binders, Calcium-Based Phosphate Binders, Others); Indication (Late Stage Chronic Kidney Disease Induced Hyperparathyroidism, Late Stage Chronic Kidney Disease Induced Hyperphosphatemia, Late Stage Chronic Kidney Disease Induced Hyperkalaemia); Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies); and Country
Calcimimetics segment by product type is estimated to lead the market growth during the forecast period
According to a new market research study of “Midldle East and AfricaLate Stage Chronic Kidney Disease Drugs MarketForecast to 2027 - COVID-19 Impact and Analysis by ProductType, Indication, Distribution Channel and Country.” The Middle East and Africa late stage chronic kidney disease drugs market is expected to reach US$ 294.07 million in 2027 from US$ 143.27 million in 2019. The market is estimated to grow with a CAGR of 9.6% from 2020 to 2027. The report highlights trends prevailing in the Middle East and Africa Late Stage Chronic Kidney Disease Drugs Market and the factors driving market along with those that act as hindrances.
Middle East and Africalate stage chronic kidney disease drugs market,based on product type, has been segmented into calcimimetics, vitamin D, potassium binders, calcium-based phosphate binders, and others. The calcimimetics segment held the largest share of the market in 2019, whereas the same segment is anticipated to register the highest CAGR in the market during the forecast period. The late-stage renal disease is characterized by the loss of kidney’s ability to filter waste and excess fluid from blood, leadings to waste accumulation in the body. Chronic kidney disease (CKD) is a common and life-threatening condition that affects 1 in 10 people in the world. As per the Lancet Global Health report published in December 2019, the overall prevalence of chronic kidney disease in South Africa was 15.8%, and the number of people opting for the treatment of the same is expected to increase with the mounting awareness regarding this condition. Moreover, the rising prevalence of high blood pressure and diabetes is a major cause of the progression of end-stage kidney disease (ESKD). These factors are expected to enhance market growth during the forecast period. Also, various strategies proposed by the World Health Organisation (WHO) to support policymakers in developing suitable policies, encompassing the vital medicine list concept and the universal health coverage (UHC) approach would boost the market growth in the coming years.
Key factors that are driving growth of the Middle East and Africa late stage chronic kidney disease drugs market arehigh prevalence of diseases leading to chronic kidney diseases and favorable reimbursement policy for the late stage chronic kidney disease drugs. However, delay in the diagnosis of chronic kidney disease is likely to hamper the growth of the market during the forecast period.
AbbVie Inc., Amgen and AstraZeneca are among the leading companies operating in theMiddle East and Africalate stage chronic kidney disease drugs market .
The report segments inMiddle East and Africa late stage chronic kidney disease drugs market as follows:
By Product Type
- Vitamin D
- Potassium Binders
- Calcium-Based Phosphate Binders
- Late Stage Chronic Kidney Disease Induced Hyperparathyroidism
- Late Stage Chronic Kidney Disease Induced Hyperphosphatemia
- Late Stage Chronic Kidney Disease Induced Hyperkalaemia
By Distribution Channel
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
- Saudi Arabia
- South Africa
- Rest of Middle East and Africa
Contact Person: Sameer Joshi
Email Id: firstname.lastname@example.org